The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue EMBO Molecular Medicine Année : 2017

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism

Jacques Cadranel
  • Fonction : Auteur
  • PersonId : 901162
Nathalie Mathiot
  • Fonction : Auteur
Ariel Savina
  • Fonction : Auteur

Résumé

Although lung cancer patients harboring EGFR mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKI), most of them rapidly relapse. RHOB GTPase is a critical player in both lung carcinogenesis and the EGFR signaling pathway; therefore, we hypothesized that it could play a role in the response to EGFR-TKI. In a series of samples from EGFR-mutated patients, we found that low RHOB expression correlated with a good response to EGFR-TKI treatment while a poor response correlated with high RHOB expression (15.3 versus 5.6 months of progression-free survival). Moreover, a better response to EGFR-TKI was associated with low RHOB levels in a panel of lung tumor cell lines and in a lung-specific tetracycline-inducible EGFR L858R transgenic mouse model. High RHOB expression was also found to prevent erlotinib-induced AKT inhibition in vitro and in vivo. Furthermore, a combination of the new-generation AKT inhibitor G594 with erlotinib induced tumor cell death in vitro and tumor regression in vivo in RHOB-positive cells. Our results support a role for RHOB/ AKT signaling in the resistance to EGFR-TKI and propose RHOB as a potential predictor of patient response to EGFR-TKI treatment.

Mots clés

Fichier principal
Vignette du fichier
238.full.pdf (1.83 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-01504463 , version 1 (10-04-2017)

Licence

Paternité

Identifiants

Citer

Olivier Calvayrac, Julien Mazières, Sarah Figarol, Claire Marty‐detraves, Isabelle Raymond‐letron, et al.. The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism. EMBO Molecular Medicine, 2017, 9 (2), pp.238 - 250. ⟨10.15252/emmm.201606646⟩. ⟨hal-01504463⟩
475 Consultations
156 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More